AMALY — SHARIAH COMPLIANCE REPORT
==================================
Symbol: ONCY
Report Date: 2026-07-10
Full Report: https://amaly.io/stock/ONCY

EXECUTIVE SUMMARY
------------------
Compliance Status: NON_COMPLIANT
Quality Rating: B
Description: This report evaluates Oncocyte Corporation (ONCY), a biotechnology firm specializing in cancer diagnostics, for Shariah compliance. Financial ratios indicate strong performance in debt and liquidity metrics, but insufficient income data leads to some uncertainties. Business activities are permissible, with no non-compliant revenue sources identified. Index inclusion research shows no presence in major Shariah indices, resulting in non-compliant status despite favorable ratios. Overall, the stock requires monitoring for data completeness and potential future index eligibility.

Primary Compliance Concerns:
- Insufficient data for interest income and non-permissible income ratios, leading to review status in some standards
- Unknown industry classification complicates benchmarking and peer comparisons
- No inclusion in major Shariah indices despite compliant financial ratios

Purification Requirement: 0.00%
Index Inclusion: Not included in any of the four major Shariah-compliant indices

KEY FINANCIAL METRICS
----------------------
Debt Ratio: 1.3%
Liquidity Ratio: 20.3%
Interest Income Ratio: 0.0%
Purification Required: 0.00%

INDEX INCLUSION STATUS
-----------------------
S&P Shariah: EXCLUDED
MSCI Islamic: EXCLUDED
DJIM: EXCLUDED
FTSE Shariah: EXCLUDED
Total: 0 of 4
Last Verified: 2026-01-31

REPORTING PERIOD
-----------------
Latest Annual Report: FY 2025
Latest Quarterly Data: Q4 2025
Trend Period: FY 2020 to FY 2025
Data Retrieved: 2026-02-17T12:00:00Z

---
Full interactive report: https://amaly.io/stock/ONCY
Provided by Amaly (https://amaly.io) — Shariah Compliant Stock Screener
Disclaimer: This data is for informational purposes only and does not constitute financial or religious advice.